Moleculin Biotech, Inc. has released its financial results for the third quarter of 2026, showcasing notable advancements in its pivotal MIRACLE trial for Annamycin, a treatment for relapsed or refractory acute myeloid leukemia (AML). This update is significant as it positions the company for potential breakthroughs in a competitive pharmaceutical landscape.
On November 16, 2026, Moleculin Biotech announced its financial results for the quarter ending September 30, 2026, and detailed progress in its clinical development programs. The company reported the completion of treatment for all 90 patients in Part A of the MIRACLE trial, which is crucial for evaluating Annamycin's effectiveness.
Background
Moleculin Biotech, Inc. is a Delaware-based company focused on developing innovative treatments for cancer. The company operates under the Standard Industrial Classification (SIC) code 2834, which pertains to Pharmaceutical Preparations. It trades on the Nasdaq under the ticker symbol MBRX. Recent filings include an 8-K on November 16, 2026, and a 10-Q on November 13, 2026.
What the Filing Says
The 8-K filing indicates that Moleculin Biotech has completed treatment for all patients in Part A of the MIRACLE trial and is on track for a comprehensive data readout in the first quarter of 2027. The filing states, "The Company remains on track to report comprehensive Part A data in the first quarter of 2027, supporting optimal dose selection and planned initiation of Part B." This data is expected to inform the next steps in the trial.
Impact
This announcement is likely to affect various stakeholders, including investors, healthcare professionals, and patients. Investors will be keenly interested in the upcoming data readout, while healthcare professionals may look for insights into Annamycin's potential as a treatment option for AML. The pharmaceutical industry, particularly companies developing cancer therapies, will also be watching closely as this trial progresses.
What's Next
The filing does not specify what happens next beyond the anticipated data readout in early 2027. However, the completion of Part A of the MIRACLE trial and the subsequent data analysis will be critical for Moleculin's strategic direction and potential market impact.
Read Next
Vanjia Corp reports Q3 2026 financial results
Sparxx Corp reports Q3 2026 results, shows growth trends
iWallet Corp Reports Q3 Results, Highlights Financial Strategy
HarbourVest Private Equity Secondaries Fund Reports Q2 Results
INVO Fertility Reports 28% Revenue Growth in Q3 Results
KEEMO Fashion Group Reports No Revenue in Latest 10-Q Filing








